Encapsulated human primary islet allografts
Phase 1- Indications
- Type 1 diabetes
Company intelligence / Profile preview
Novocell, Inc.
San Diego, California, United Statesnovocell.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
The original Novocell developed a process to efficiently convert human embryonic stem cells into insulin-producing pancreatic endocrine cells and was conducting clinical trials examining safety and efficacy of encapsulated human primary islet allografts in patients with Type 1 diabetes[2][5]
- Therapeutic areas
- OtherEndocrinology
- Modalities
- Stem cell-derived therapiesCell encapsulation technology
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Beyond the preview
Go deeper on Novocell, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novocell, Inc..